Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs D Wave Quantum Inc (QBTS) Price & Performance

Adaptive Biotechnologies CorpTrade
D Wave Quantum IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs D Wave Quantum Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.95 (market cap $4.04B), while D Wave Quantum Inc trades at $20.55 (market cap $7.53B). The key difference: D Wave Quantum Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.

ADPTQBTS
Market Cap
$4.04B$7.53B
Sector
HealthTechnology
52-Week High
$25.45$44.78
52-Week Low
$12.30$12.98
Enterprise Value
$4.10B$7.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

D Wave Quantum Inc

QBTS trades at $20.55, up 1.78% today, with a bearish technical signal despite 100% analyst buy ratings. The stock shows extreme valuation with a P/S of 583.84 and negative profitability, including a net income margin of -2,001.59% for 2026. Recent Q2 2026 earnings missed revenue and EPS estimates, though bookings surged 1,120%, highlighting growth potential amid financial strain. Cash flow trends indicate heavy investment outlays, with net cash flow turning negative in 2026.

Outlook remains speculative; the consensus price target of $38.29 offers significant upside, but high execution risks persist. Investors face volatility from unproven commercial scaling, reliance on financing, and competitive quantum computing pressures. The stock's appeal hinges on future revenue conversion from bookings, making it suitable for risk-tolerant investors betting on long-term quantum adoption.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS